Viatris: From Pfizer Legacy to Underestimated Turnaround Case

Viatris generates reliable billion-dollar cash flows through the global distribution of off-patent but brand-strong original medications and technologically complex generics. To escape the price decline in standard generics, the company focuses strategically on high-margin therapy niches such as ophthalmology, gastroenterology, and dermatology after a strict debt reduction. The stock combines an attractive value assessment and reliable payouts with recovery potential, provided the strategic realignment outperforms the gradual revenue loss...